Colistin-Resistant Acinetobacter baumannii: Beyond Carbapenem Resistance
Zubair QureshiLauren HittleJessica A. O’HaraJesabel I. RiveraAlveena SyedRyan K. ShieldsA. William PasculleRobert K. ErnstYohei Doi
Abstract
Colistin-resistant A. baumannii occurred almost exclusively among patients who had received CMS for treatment of carbapenem-resistant, colistin-susceptible A. baumannii infection. Lipid A modification by the addition of phosphoethanolamine accounted for colistin resistance. Susceptibility testing for colistin should be considered for A. baumannii identified from CMS-experienced patients.
Metrics
Citation History
Topics
Related Documents
Colistin-resistant Acinetobacter baumannii
Nadia JaidaneCherifa ChaouechAziza MessaoudiNoureddine BoujâafarOlfa Bouallègue
EFFICACY OF COLISTIN AND CEFIDEROCOL ON CARBAPENEM RESISTANT Acinetobacter baumannii ISOLATES
Feyza BalciNilgün KansakSebahat Aksaray
Genomic investigation unveils colistin resistance mechanism in carbapenem-resistant Acinetobacter baumannii clinical isolates
Saranya VijayakumarRayapadi G. SwethaYamuna Devi BakthavatchalamKarthick VasudevanBaby Abirami ShankarAgilandeeswari KirubananthanKāmini WaliaSudha RamaiahIndranil BiswasBalaji VeeraraghavanAnand Anbarasu
Colistin and Carbapenem-Resistant Acinetobacter baumannii Aci46 in Thailand: Genome Analysis and Antibiotic Resistance Profiling
Nalumon ThadtapongSoraya ChaturongakulSunhapas SoodvilaiPadungsri Dubbs